摘要
目的探讨新辅助化疗对晚期乳腺癌组织中雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER-2）表达的影响。方法收集ⅡB~ⅢB期的局部晚期乳腺癌患者48例,应用免疫组化方法检测ER、PR和HER-2的表达后,给予表阿霉素（EPI）加多西紫杉醇（DOX）方案进行新辅助化疗,3个疗程后行根治手术,将术后标本中ER、PR和HER-2的表达与化疗前表达情况进行对照,分析新辅助化疗对免疫表达的影响。结果新辅助化疗前ER阳性表达率为33.3%,化疗后ER阳性表达率为52.1%;化疗前PR阳性表达率为35.4%,化疗后PR阳性表达率为50.0%。ER和PR阴性表达的患者在新辅助化疗后转为阳性表达的比例高于化疗前阳性转为阴性的比例,但差异没有统计学意义（P〉0.05）。新辅助化疗前HER-2阳性表达率为62.5%,化疗后HER-2阳性表达率为52.1%,新辅助化疗后阳性转阴率略高于阴性转阳率,差异无统计学意义（P〉0.05）。结论新辅助化疗能使部分乳腺癌组织中ER、PR和HER-2的表达发生改变,为乳腺癌的治疗提供了一定的依据。
Objective To study the effect of neoadjuvant chemotherapy on the expressions of estrogen receptor（ ER）,progesterone receptor（ PR）,C-erbB-2 in the curative effect of chemotherapy on breast cancer.Methods The expressions of ER,PR,and C-erbB-2 before and after operation were measured by immunohistochemical staining method in 48 patients.All the patients received 3 cycles of EPI and DOX chemotherapy regimen,after 3 cycles of chemotherapy modified radical mastectomy was performed and the ER,PR,C-erbB-2 expression was measured again.To compare the positive expression before and after neoadjuvant chemotherapy.Results The diference of ER,PR and C-erbB-2 before and after neoadjuvant chemotherapy were insignificant（ P 〉0.05）.Conclusion Neoadjuvant chemotherapy can influent the status of ER,PR,C-erbB-2 in partial breast cancer tissues which could be helpful to the diagnosis and therapy of breast cancer.
出处
《中国肿瘤临床与康复》
2014年第10期1158-1160,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
河北省科技立项课题(编号:201101A250)
